NERV - Minerva Neurosciences Corp Market Capitalization-to-Revenue Ratio
Investor caution following FDA claims has pressured quotes, as illustrated by the P/S market multiple. The current level of reflects the valuation of Minerva Neurosciences (NERV), a business developing tools for the social adaptation of schizophrenia patients. The stability of Minerva Neurosciences (NERV) is based on patents for the therapy of sleep disorders and chronic psychoses, which ensure endless demand for its products.
Metric breakdowns and analytics for Minerva Neurosciences Corp (NERV)
- stock value and consensus price forecast:
- market capitalization statistics:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Minerva Neurosciences|NERV - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Minerva|NERV - Company Debts|Debts to Book Value Minerva Neurosciences Corp|NERV - Company Long-Term Debt|Short-Term Debt Volume Minerva Neurosciences|Quick Liquidity Indicator minervaneurosciences.com
- net income and valuation multiples indicators:
NERV - Net Profit|Company Profit Forecast Minerva Neurosciences|NERV - P/E Multiple|Projected Price to Earnings Ratio Minerva Neurosciences Inc|NERV - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Minerva Neurosciences Corp|NERV - Operating profit EBITDA|Net earnings per share for the last 12 months Minerva Neurosciences|NERV - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months minervaneurosciences.com|NERV - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Minerva Neurosciences
- issuer revenue and sales details:
Fundamental company analysis:NERV - minervaneurosciences.com
Stable demand for schizophrenia treatments provides Minerva Neurosciences (NERV) with high macroeconomic resilience. By analyzing the price-to-sales multiple, an investor compares current market capitalization with the actual volume of generated revenue. This ratio determines the cost of each dollar of sales, making it possible to distinguish fundamental growth from speculative overheating. Such a valuation confirms the investment attractiveness of a non-cyclical biotech company whose revenues remain independent of market conditions.
Competitors of Minerva Neurosciences
P/S Multiple biogen.com (BIIB)|Neurocrine Biosciences, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RGC|AXSM - Price-to-Revenue Ratio|ACAD (ACADIA Corp) - Market Cap to Revenue Ratio|XENE: P/S Multiple|Price to Sales vikingtherapeutics.com (VKTX)|Market Cap to Revenue SUPN|P/S Multiple Catalyst Pharma|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|HRMY (Harmony Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Biohaven Ltd. BHVN|amylyx.com (AMLX) - Price to Sales|TRVI - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Praxis Precision Medicines Inc PRAX|AVXL: P/S Multiple|Market Cap to Revenue CeriBell EEG|PRTA (Prothena Biosciences) - P/S Multiple|Alector Therapeutics (ALEC) - Price-to-Revenue Coefficient|P/S Multiple ANNX|OMER - Price to Sales|Price-to-Revenue Ratio Neurogene Corp NGNE|ACIU: Market Cap to Revenue Ratio|Voyager Therapeutics - P/S Multiple|neumoratx.com (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|Price to Sales Tevogen Bio Holdings Inc. (TVGN)|Price-to-Revenue Ratio Alpha Cognition Inc|Cognition Therapeutics Inc. (CGTX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Inhibikase Therapeutics (IKT)|cassavasciences.com - Market Cap to Revenue Ratio|P/S Multiple ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Price to Sales|VTGN - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio OVID (Ovid Therapeutics Inc.)|ABOS (Acumen Pharmaceuticals) - Market Cap to Revenue|CRVO (cervomed.com) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|Market Cap to Revenue Ratio CLNN (Clene Nanomedicine)|P/S Multiple PEPG|JUNS - Price to Sales|Relmada Therapeutics - Market Cap to Revenue|P/S Multiple annovisbio.com ANVS|GRCE - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio AIFF (Firefly Neuroscience, Inc.)|anewmeds.com (KLTO) - Price-to-Revenue Ratio|Price to Sales NeuroSense Therapeutics Ltd. (NRSN)|Price-to-Revenue Ratio Reviva Pharmaceuticals|Market Cap to Revenue MetaVia, Inc. (MTVA)|P/S Multiple NRXS|Price-to-Revenue Coefficient heliusmedical.com|Price-to-Revenue Ratio Passage Bio PASG|NEUP: Market Cap to Revenue Ratio|Athira Pharma, Inc. - P/S Multiple|Price to Sales addextherapeutics.com|alzamend.com (ALZN) - Price-to-Revenue Ratio|Cyclerion Therapeutics, Inc. - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue PTIX|Price-to-Revenue Ratio KTTA|P/S Multiple CRGT|P/S Multiple avenuetx.com (ATXI)|BrainStorm Cell Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CARA|CHRO - Price-to-Revenue Ratio|ELYM (Eliem Therapeutics) - Market Cap to Revenue Ratio|ITCI: P/S Multiple|Price to Sales longboardpharma.com (LBPH)|Market Cap to Revenue MRNS|P/S Multiple NKGen Biotech Inc|Price-to-Revenue Ratio NeuroBo (NRBO)|SAGE (Sage Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|trevena.com (TRVN) - Price to Sales|VIGL - Price-to-Revenue Ratio|Price-to-Revenue Coefficient anewmeds.com WENA|CERE: P/S Multiple
